Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Seagram’s Escapes Spiked Drops Limited-Time WWE Variety Pack with Bold Flavor

April 6, 2026

Sezzle’s Super App Dominates Financial Literacy Month as MoneyIQ Game Engagement Spikes

April 6, 2026

Take 5 Oil Change Brings Its Stay-in-Your-Car Service to Corsicana with First Local Shop

April 6, 2026

KIPRUN OFFICIALLY LAUNCHES IN THE U.S. MARKET

April 6, 2026

BLAQclouds, Inc. Launches $1,000 theAlley.io Growth Challenge Beginning April 6, 2026 at 8:00 AM EDT

April 6, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth
Press Release

Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth

By News RoomApril 2, 20264 Mins Read
Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Gliosarcoma Market Report 2026” has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive insights, covering global market size, regional shares, market trends, and strategic opportunities for stakeholders.

The gliosarcoma market has experienced notable expansion in recent years, with a projected growth from $1.25 billion in 2025 to $1.32 billion in 2026, at a compound annual growth rate (CAGR) of 5.3%. This growth is underpinned by limited clinical understanding, advances in neuro-pathology, the growth of oncology research institutes, improved imaging technologies, and enhanced academic research interests.

Looking ahead, strong growth is anticipated as the market climbs to $1.6 billion by 2030, at a 5% CAGR. Key drivers include increased funding for rare cancer research, precision diagnostics development, refined treatment protocols, molecular testing expansion, and heightened research center collaborations. Trends projected for this period involve expanded research on rare brain tumors, molecular diagnostics advancements, and the refinement of multimodal treatment strategies, alongside improved diagnostic accuracy.

The rising incidence of brain tumors is expected to further drive market growth. Enhanced diagnostic technologies, greater awareness, and lifestyle factors contributing to risk exposure have led to an increase in brain tumor incidences. Effective gliosarcoma treatment is critical for managing symptoms and improving patients’ quality of life. The increasing incidence emphasizes the necessity of these treatments, demonstrated by data from Dementia Australia, which shows a steep rise in dementia cases, indicative of broader neuro-oncological challenges.

Leading companies in the sector are embracing advanced technological solutions, such as wearable devices, for health monitoring and patient engagement. For example, in November 2024, Novocure Ltd. secured FDA approval for new Head Flexible Electrode (HFE) transducer arrays used with Optune Gio, enhancing glioblastoma multiforme (GBM) treatment through Tumor Treating Fields (TTFields) technology. These innovations underscore the commitment to improving patient outcomes.

Strategic acquisitions, such as Merck & Co. Inc.’s $1.3 billion acquisition of Modifi Biosciences in October 2024, enhance portfolios in glioblastoma and broader cancer therapies, showcasing industry moves towards advanced treatments. Prominent market players include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, and others, highlighting a competitive landscape focused on innovation and patient care.

Regionally, North America was the largest market in 2025, with Asia-Pacific poised as the fastest-growing region through the forecast period. The market encompasses diverse geographies such as Western and Eastern Europe, South America, and numerous emerging markets in Asia and Africa. As the industry adapts to challenges like tariffs affecting import costs, domestic innovation in diagnostics gains momentum, supporting localized advancements.

Reasons to Purchase:

  • Acquire a global perspective with unparalleled market coverage across multiple geographies.
  • Analyze the impact of macro factors such as geopolitical tensions, trade policies, inflation, interest rate fluctuations, and regulatory changes.
  • Formulate regional and country-specific strategies informed by local data and analysis.
  • Identify promising growth segments for strategic investments.
  • Leverage forecast data and market drivers to excel beyond competitors.
  • Enhance understanding of customer segments through detailed end-user analysis.
  • Benchmark against competitors using market share, innovation, and brand strength metrics.
  • Determine market potential with a total addressable market analysis and attractiveness scoring.
  • Utilize reliable data for both internal and external strategic presentations.
  • Access an up-to-date report with new data, supported by an Excel data sheet for easy analysis.
  • Receive comprehensive data in an excel dashboard format for enhanced usability.

Report Scope

Markets Covered:

  • Diagnosis Method: Imaging Techniques, Histopathological Examination, Biomarker Testing
  • Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
  • End-User: Hospitals, Cancer Research Institutes, Specialty Clinics

Subsegments:

  • Imaging Techniques: MRI, CT Scan, PET Scan
  • Histopathological Examination: H&E Staining, IHC, Electron Microscopy
  • Biomarker Testing: IDH Mutation Testing, MGMT Promoter Methylation Testing, ATRX Mutation Testing, TP53 Mutation Analysis

Countries Covered: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series: Five years historic and ten years forecast data.

Data and Segmentation: Consists of market size ratios, growth related to GDP proportions, expenditure per capita, and country and regional historic and forecast data. Includes market share of competitors and segmentation.

Key Attributes

Report Attribute Details
No. of Pages 250
Forecast Period 2026-2030
Estimated Market Value (USD) in 2026 $1.32 Billion
Forecasted Market Value (USD) by 2030 $1.6 Billion
Compound Annual Growth Rate 5%
Regions Covered Global

The companies featured in this Gliosarcoma market report include:

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Bio-Rad Laboratories Inc.
  • Carl Zeiss AG
  • Elekta AB
  • Novocure Ltd.
  • ImmunityBio Inc.
  • Immatics Biotechnologies
  • Karyopharm Therapeutics Inc.
  • Kintara Therapeutics Inc.
  • Aveta Biomics Inc.
  • Vigeo Therapeutics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/4qnkzx

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Seagram’s Escapes Spiked Drops Limited-Time WWE Variety Pack with Bold Flavor

Sezzle’s Super App Dominates Financial Literacy Month as MoneyIQ Game Engagement Spikes

Take 5 Oil Change Brings Its Stay-in-Your-Car Service to Corsicana with First Local Shop

KIPRUN OFFICIALLY LAUNCHES IN THE U.S. MARKET

BLAQclouds, Inc. Launches $1,000 theAlley.io Growth Challenge Beginning April 6, 2026 at 8:00 AM EDT

3 E Network Announces Progress Update on Finland AI Data Centre Project: Site Clearance Completed and Earthworks Underway

Papa Johns Canada Introduces Spinach Alfredo Chicken Tomato Pizza

Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High

Toobit Announces Exclusive Presale for Solitaire Blossom (SOLIB) on Launchpad

Editors Picks

Sezzle’s Super App Dominates Financial Literacy Month as MoneyIQ Game Engagement Spikes

April 6, 2026

Take 5 Oil Change Brings Its Stay-in-Your-Car Service to Corsicana with First Local Shop

April 6, 2026

KIPRUN OFFICIALLY LAUNCHES IN THE U.S. MARKET

April 6, 2026

BLAQclouds, Inc. Launches $1,000 theAlley.io Growth Challenge Beginning April 6, 2026 at 8:00 AM EDT

April 6, 2026

Latest News

Alberta snowpacks much deeper thanks to heavy snowfall

April 6, 2026

3 E Network Announces Progress Update on Finland AI Data Centre Project: Site Clearance Completed and Earthworks Underway

April 6, 2026

Can AI responses be influenced? The SEO industry is trying

April 6, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version